fourth everybody, you and Thanks, Kathy. Good morning, year for quarter joining end thank our and call. conference
think in half our the at goal XX. to do and month year speak of sharing continues which trial database line Zimura GA, European expectations for for Medicines after in about forward the injection exceed will to focus well on needed be the plus of lock in our to clinical the X the file of atrophy execution, time US continue of approval or as Agency greater we to of We XXXX, As the to will GATHERX, patient Zimura the we If with an enrollment second This Phase applications are XX% for than positive, analysis, you GA. as Keith rate data and XX-month evidenced FDA, second know as moments. which by to well geographic treatment the few stated year. last the fidelity with as approximately look the above marketing a results we plan one top
As data, the to to of prepare efforts reporting GA. the Zimura closer we continued treatment for a our of for get potential we drug GATHERX for application internally new filing
Commercial two to infrastructure the our gain Desai, continue and experience our experienced affairs at with Officer, Chief Chris led and We momentum led well-seasoned out by commercial building and leaders potential. working are blockbuster medical Officer. Development These retinal our Chief with by team Simms, Dhaval drugs launching in
Zimura execute Earlier Trademark on and IP issued, treat of patent, this covering Office strategy once the methods US to patent of continue our We use allowed expire The month, GA. Patent expected is for to for XXXX. claims to Zimura. in
our We’re GA subset of the announce a to patients evaluated trial was fovea the Phase by were on GATHERX, details GA. from post-hoc you progression provide to will of results disease few see moments a the Pravin that analysis within excited this the a recently and regions new Zimura X and also in year’s we this of conference, the rate and data. Exudation These growth in why data treatment in Angiogenesis, clinical for analysis excited the more quite of parameters which are presented in explore analysis Degeneration at will various
we of groundwork XXXX over back successfully laid think to believe milestones for us. a a for the we have achieved that we be major year, As banner past the number year
highlights. recap me some briefly significant Let of the
for file an Protocol XX endpoint meets marketing US solidifies agreement approval written months. of plans for Assessment Zimura the our GATHERX. primary FDA a under further a the SPA received The trial GA at clinical FDA if we design GATHERX the or ongoing First, of to the its Special agreement from NDA for overall with
its met at July of This with our GATHERX completion Zimura endpoint was schedule. patient announced enrollment know, four the we you ahead completed in primary trial. XX in efficacy As of pivotal months In a statistical previously GATHERX. significance months original
We also clinical year. to Phase half planning started in Zimura initiate trial X patients second of AMD in this a with intermediate the studying the
patients for our is We trial. trial treatment in Stargardt Zimura of disease. continue This to clinical autosomal of Xb screening enroll our Phase recessive STAR
number of IC-XXX, for a HtrAX We studies also pharmacokinetics our inhibitor. and preclinical initiated tolerability
However, of the IND-enabled This to is the we of studies planned. in pandemic. or later originally slots start contract of research the that COVID-XX study the anticipate organizations lack availability availability than due wake primarily tox will that be of
Drug expect to for submit the an during the for Investigational Application IC-XXX New FDA to an IND We mid-XXXX.
our and preparations We million enabled proceeds and accelerate Zimura launch to potential also call. strengthen XXXX by capacity. the raising continue balance to allow capital net to public raise these approximately in that July runway October XXX of believe and We Dave offerings in sheet XXX from will in manufacturing us for cover cash us million commercial and cash our later invest in respectively.
the continue invest initiatives AMD trial in in patient initiation investing of multiple delivery technologies. money In additional the to expand release for population with indications, lifecycle to additional order such and an we Zimura addition, in sustained as intermediate
Officer Christine On Miller front, and welcome who’s President Directors. of to to Executive Chief the the Therapeutics Melinta of Board excited we’re corporate our
our We’re a and be background Christine’s supply caliber thrilled management our join chain have Christine’s on Board to will of extensive Directors. addition commercialization to valuable of board. somebody
I our call a in Keith. strategy over biotech to look Business ask about this and, as known and like throughout joined to to our words Tony We also, Tony I’d former to mentioned, He Tony to is us an well now Kathy investment banker the industry. just We’re turn on executive success. in you know, past as welcome Officer excited development leadership Tony’s and experienced December. is say will to to Chief forward extensive experience our few business our this and Strategy Gibney future later company. contributing call.
